270
Participants
Start Date
December 25, 2023
Primary Completion Date
June 30, 2027
Study Completion Date
June 30, 2028
Voclosporin（QL1074）
QL1074 23.7 mg BlD will be administered as a fixed dose without the use of therapeutic drugmonitoring. The protocol contains provisions for management of dose based on safety concerns, in particular, BP and renal function，can be managed by dose reduction and temporary of QL1074 to interruption.
Placebo
Placebo softgel capsules, identical to 7.9 mg QL1074, will be provided. The administration plan and dosage management regulations are the same as QL1074.
RECRUITING
The First Affiliated Hospital of Bengbu Medical University, Bengbu
RECRUITING
The People's Hospital of Bozhou, Bozhou
RECRUITING
Anhui Provincial Hospital, Hefei
RECRUITING
The Second Affiliated Hospital of Anhui Medical University, Hefei
RECRUITING
Chincse PLA General Hosptial, Beijing
NOT_YET_RECRUITING
Peking University First Hospital, Beijing
RECRUITING
Fujian Medical University Union Hospital, Fuzhou
RECRUITING
The First Affiliated Hospital of Dalian Medical University, Dalian
RECRUITING
Huashan Hospital, Shanghai
RECRUITING
Heping Hospital Affiliated to Changzhi Medical College, Changzhi
Qilu Pharmaceutical Co., Ltd.
INDUSTRY